## Biotin-NH-PSMA-617

Cat. No.:	HY-141729			
Molecular Formula:	C <sub>65</sub> H <sub>97</sub> N <sub>13</sub> O <sub>19</sub> S			
Molecular Weight:	1396.61			
Target:	Fluorescent Dye			
Pathway:	Others			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	6 months	
		-20°C	1 month	

### SOLVENT & SOLUBILITY

# In Vitro

DMSO : ≥ 50 mg/mL (35.80 mM)

\* " $\geq$ " means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	0.7160 mL	3.5801 mL	7.1602 mL
	5 mM	0.1432 mL	0.7160 mL	1.4320 mL
	10 mM	0.0716 mL	0.3580 mL	0.7160 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIV	
Description	Biotin-NH-PSMA-617 is a biotin-tagged PSMA-617. PSMA-617 is a small molecule targeting the prostate-specific membrane antigen (PSMA), which is directly expressed by the tumor cells <sup>[1]</sup> .
In Vitro	PSMA-617 is a PSMA ligand. PSMA-617 shows a significantly improved binding affinity to PSMA as well as a highly efficient internalization into PCa cells. PSMA-617 can be labeled with <sup>68</sup> Ga, <sup>177</sup> Lu, <sup>111</sup> In, and <sup>90</sup> Y and, therefore, be used for PET-imaging as well as for radioligand-based therapy <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### REFERENCES

[1]. Kratochwil C, et al. Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;45(1):31-37.

[2]. Afshar-Oromieh A, et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. J Nucl Med. 2015;56(11):1697-1705.



NHH HN H S



### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA